The Cancer Market Outlook to 2016

Date: June 22, 2011
Pages: 164
Price:
US$ 3,835.00
Publisher: Business Insights
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C8E165371CEEN
Leaflet:

Download PDF Leaflet

The Cancer Market Outlook to 2016
Introduction

The global cancer market is becoming increasingly competitive, with two therapeutic classes, namely antineoplastics and cytostatic hormonal treatments, dominating this sector. This report presents leading products, developments, and market forecasts for each of these classes. Eighteen recently launched/late-stage pipeline products are discussed in detail.

Features and benefits

  • Understand how recent events are affecting the performance of major products, and how companies are confronting competitive market changes.
  • Compare the franchises of the leading companies in the cancer market, and understand how the market share of these companies will change.
  • Assess key pipeline products by indication, ongoing trials, recent product launches, and key developments in R&D.
  • Identify the challenges faced by leading players, and understand how recent events will impact the performance of leading products.
  • Gain insights into the forecasts of the leading marketed and pipeline products through to 2016.


Highlights

The key factor for growth of the cancer therapy market is the expansion of target indications. Most of the blockbuster drugs were launched for a narrow indication, but later gained approval for a wider range of indications.

Regardless of indication, the key challenge in ensuring the commercial success of pipeline drugs is to ascertain their integration into current treatment regimens either in combination with existing therapies or by demonstrating significant superiority over current treatments.

Pricing risk remains the key investment concern in cancer. Moreover, the level of scrutiny by payers regarding the cost-effectiveness of cancer treatments has intensified in recent years.

Your key questions answered
  • What will be the major growth indications and the accompanying growth drivers in the cancer market over the next 6 years?
  • Which were the leading players in the cancer market in 2010?
  • Which products will be the future growth drivers for the cancer health market?
  • Which therapeutic categories are forecast to have the highest levels of commercial potential over the period 2010–16?
  • Which companies are best positioned to succeed in the cancer market over the period 2010–16?
EXECUTIVE SUMMARY

Overview and epidemiology of cancer
Global market analysis
Pipeline analysis
Competitive landscape

ABOUT BUSINESS INSIGHTS

Disclaimer

OVERVIEW AND EPIDEMIOLOGY OF CANCER

Summary
Introduction
Overview
Cancer risk factors
  Chemical carcinogens
  Age
  Tobacco smoke
  Lifestyle factors
  Radiation
  Immune system
  Genetics
Lung cancer
  Overview
  Diagnosis, treatment, and management
  Epidemiology
  Forecast epidemiology
Colorectal cancer
  Overview
  Diagnosis, treatment, and management
  Epidemiology
  Forecast epidemiology
Breast cancer
  Overview
  Diagnosis, treatment, and management
  Epidemiology
  Forecast epidemiology
Ovarian cancer
  Overview
  Diagnosis, treatment, and management
  Epidemiology
  Forecast epidemiology
Uterine and cervical cancer
  Overview
  Diagnosis, treatment, and management
  Epidemiology
  Forecast epidemiology
Leukemia
  Overview
  Diagnosis, treatment, and management
  Epidemiology
  Forecast epidemiology
Prostate cancer
  Overview
  Diagnosis, treatment, and management
  Epidemiology
  Forecast epidemiology
Pancreatic cancer
  Overview
  Diagnosis, treatment, and management
  Epidemiology
  Forecast epidemiology
Lymphomas
  Overview
  Diagnosis, treatment, and management
  Epidemiology
  Forecast epidemiology
Head and neck cancer
  Overview
  Diagnosis, treatment, and management
  Epidemiology
  Forecast epidemiology

GLOBAL MARKET ANALYSIS

Summary
Introduction
Market analysis by country
Market analysis by drug class
Leading brand dynamics
  Avastin (bevacizumab) – Roche
  Herceptin (trastuzumab) – Roche
  MabThera (rituximab) – Roche
  Taxotere (docetaxel) – Sanofi
  Alimta (pemetrexed) – Eli Lilly
Key recent events in the cancer market
  Amgen/Takeda’s motesanib fails Phase III trial in lung cancer
  Merck Serono files expanded approval for Erbitux (cetuximab) in the EU
  Abbott signs a deal with Seattle Genetics for antibody drug conjugate (ADC) technology
  Strides’ carboplatin approved in European markets
  Herceptin receives approval for gastric cancer in Japan
  NICE revises its decision for MabThera as a maintenance treatment
Antineoplastics
  Competitive dynamics of antineoplastics
  Leading antineoplastic brands
  Antineoplastic mAb market analysis
  Antineoplastic sales forecast
Cytostatic hormonal therapies
  Competitive dynamics of cytostatic hormonal therapies
  Leading brands of cytostatic hormonal therapies
  Cytostatic hormonal therapy sales forecast
Global cancer market sales forecast

PIPELINE ANALYSIS

Summary
Introduction
Key trends in R&D
  Targeted therapies are changing the treatment regimen of cancer
  Cancer vaccines enhance the body’s immune response
  Pricing is becoming a major issue for cancer patients
  Combination treatments are becoming the treatment of choice
Oncology pipeline
Leading drugs in development
  Recently approved/marketed drugs
  Phase III compounds
Pipeline forecast of leading drugs in development

COMPETITIVE LANDSCAPE

Summary
Introduction
Sales performance of leading players
Roche
  Sales focus by drug class
  Regional sales distribution
  Leading products
  Pipeline analysis
  Strategic and growth analysis
Eli Lilly
  Sales focus by drug class
  Regional sales distribution
  Leading products
  Pipeline analysis
  Strategic and growth analysis
AstraZeneca
  Sales focus by drug class
  Regional sales distribution
  Leading products
  Pipeline analysis
  Strategic and growth analysis
Sanofi
  Sales focus by drug class
  Regional sales distribution
  Leading products
  Pipeline analysis
  Strategic and growth analysis
Takeda
  Sales focus by drug class
  Regional sales distribution
  Leading products
  Pipeline analysis
  Strategic and growth analysis

APPENDIX

Scope
Methodology
  Market size methodology
  Epidemiology
  Market forecast
Glossary/Abbreviations
  Trial expansions
References
  Journal articles
  Clinical trials
  Important websites
Skip to top


Looking at the Cancer Therapy Market US$ 200.00 Jun, 2011 · 60 pages

Ask Your Question

The Cancer Market Outlook to 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: